DIPK2B

Across TCGA pan-cancer cohorts, DIPK2B RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of DIPK2B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where DIPK2B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DIPK2B is over-expressed in tumor, although a few such as LUAD and BLCA show the opposite, repressed pattern.

KIRC, LUAD, and BLCA are the cancer types where DIPK2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DIPK2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+2.136	<.001	12	view →
LUAD	Female	II,III,IV	−1.490	<.001	11	view →
BLCA	All	All	−1.154	<.001	11	view →
LIHC	Female	II,III,IV	+1.861	<.001	9	view →
LUSC	Male	II,III,IV	−2.078	<.001	8	view →
UCEC	All	All	−2.878	<.001	6	view →
BRCA	All	II,III,IV	−1.803	<.001	6	view →
HNSC	Female	III,IV	+1.095	.004	4	view →
CHOL	All	All	+1.767	<.001	3	view →
THCA	All	IV	−1.232	.001	3	view →
KIRP	All	All	−0.705	<.001	2	view →
READ	Female	All	−1.076	.006	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

DIPK2B–KIRC

Open the KIRC breakdown →